Compare Advance Auto Parts, Inc. (AAP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Sana Biotechnology Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.07 (market cap $3.19B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Advance Auto Parts, Inc. is far larger — about 2.8× Sana Biotechnology Inc's market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AAP | SANA | |
|---|---|---|
Market Cap | $3.19B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $5.92 |
52-Week Low | $38.75 | $2.68 |
Enterprise Value | $5.47B | $1.05B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.52, down 3.97% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.77 versus $0.39 expected, but profitability remains thin with a net income margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain improvements, as noted in recent news (The Motley Fool, August 2026).
The outlook is cautious; while valuation appears reasonable with a P/S of 0.37 and analysts set a $61.30 consensus target, weak cash flow from operations and high debt pose risks. Investor sentiment is neutral amid restructuring efforts, but margin expansion and successful execution are critical for sustained recovery.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
